ALLOZYNE

Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
ALLOZYNE
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.allozyne.com
Total Employee:
11+
Status:
Active
Contact:
206-518-5700
Email Addresses:
[email protected]
Total Funding:
36.9 M USD
Technology used in webpage:
Viewport Meta Google Analytics Google Universal Analytics AJAX Libraries API U.S. Server Location Common Name Invalid PHP Sectigo SSL Sectigo Domain SSL Shockwave Flash Embed
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
OVP Venture Partners
OVP Venture Partners investment in Series B - Allozyne
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series B - Allozyne
Amgen Ventures
Amgen Ventures investment in Series B - Allozyne
MPM Capital
MPM Capital investment in Series B - Allozyne
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Allozyne
MPM Capital
MPM Capital investment in Series A - Allozyne
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Allozyne
Amgen Ventures
Amgen Ventures investment in Series A - Allozyne
OVP Venture Partners
OVP Venture Partners investment in Series A - Allozyne
Official Site Inspections
http://www.allozyne.com
- Host name: 115.130.96.66.static.eigbox.net
- IP address: 66.96.130.115
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803

More informations about "Allozyne"
Allozyne - Wikipedia
Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic deโฆSee details»
Allozyne Company Profile 2024: Valuation, Investors, โฆ
Allozyne General Information Description. Provider of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and โฆSee details»
ALLOZYNE Overview | SignalHire Company Profile
ALLOZYNE is a private company. The company currently specializes in the Biotechnology area. The position of the CEO is occupied by Meenu Chhabra ... Organization Website: โฆSee details»
Allozyne, Inc. Company Profile | Seattle, WA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Allozyne, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Allozyne Inc - Company Profile and News - Bloomberg Markets
Company profile page for Allozyne Inc including stock price, company news, executives, board members, and contact informationSee details»
Allozyne - Products, Competitors, Financials, Employees, โฆ
Allozyne. Frequently Asked Questions (FAQ) When was Allozyne founded? Allozyne was founded in 2005. Where is Allozyne's headquarters? Allozyne's headquarters is located at 999 Third โฆSee details»
Allozyne, Inc - VentureRadar
Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. ... Dansk Biotek โฆSee details»
Allozyne - Company Profile - Tracxn
Allozyne - Protein therapeutics for CNS diseases such as multiple sclerosis.. Raised a total funding of $40.5M over 6 rounds from 6 investors. Founded by David Tirrell, Dee Datta and 1 โฆSee details»
Allozyne - Funding, Financials, Valuation & Investors - Crunchbase
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.See details»
Allozyne, Inc.:Company Profile & Technical Research,Competitor โฆ
Allozyne, Inc. is a company that provides Pharmacy and Therapeutics, Multiple sclerosis, Peptide and more. Allozyne, Inc. is headquartered in United States Washington. Allozyne, Inc. was โฆSee details»
ALLOZYNE Information - RocketReach
The NAICS codes for ALLOZYNE are [5417, 541, 54]. What is the SIC code for ALLOZYNE? The SIC codes for ALLOZYNE are [87, 873]. Top ALLOZYNE Employees Kenneth Grabstein Chief โฆSee details»
ALLOZYNE - LinkedIn
At ALLOZYNE, we demonstrate this through both of our technology platforms as well as across our pipeline to target key disease areas. Both of our platforms enable the incorporation of โฆSee details»
MedImmune acquires Allozyne - 2014-09-19 - Crunchbase
Allozyne Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. Acquiring Organization: MedImmuneSee details»
Allozyne, Inc - VentureRadar
Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. Using these โฆSee details»
Allozyne Management Team - CB Insights
Allozyne and VLST have successfully raised Series B rounds ($55M and $30M respectively) and have "graduated" from Accelerator. Prior to joining OVP, Carl was a Venture โฆSee details»
Allozymes
We can partner with pharmaceutical and manufacturing organizations. Life Sciences & Diagnostics. We are creating the next generation of enzymes which are the foundation to โฆSee details»
Allozyne - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. Search Crunchbase Start Free TrialSee details»
Allozymes Company Profile 2024: Valuation, Funding & Investors
Allozymes General Information Description. Developer of microfluidic technology designed to support the development and testing of enzymes. The company's platform helps employ โฆSee details»
Allozyne, Inc. Sold For Scrap As MedImmune Snaps Up Rights
Sep 19, 2014 The drug stays in a patientโs system longer and needs fewer doses, a boon to MS patients who have often have day-long infusion treatments. But Allozyne was competing in a โฆSee details»